This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (19) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Spence, M. M. Articles by Millares, M. Search for Related Content PubMed PubMed Citation Articles by Spence, M. M. Articles by Millares, M. Social Bookmarking                         What's this?

Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing

Kaiser Permanente

Stephanie S. Teleki

RAND

T. Craig Cheetham

Kaiser Permanente

Stuart O. Schweitzer

University of California, Los Angeles

Mirta Millares

Kaiser Permanente

Spending on direct-to-consumer advertising (DTCA) of prescription drugs has increased dramatically in the past several years. An unresolved question is whether such advertising leads to inappropriate prescribing. In this study, the authors use survey and administrative data to determine the association of DTCA with the appropriate prescribing of cyclooxygenase-2 (COX-2) inhibitors for 1,382 patients. Treatment with either a COX-2 or a traditional nonsteroidal anti-inflammatory drug (NSAID) was defined as appropriate or not according to three different definitions of gastrointestinal risk. Patients who saw or heard a COX-2 advertisement and asked their physician about the advertised drug were significantly more likely to be prescribed a COX-2 (versus a NSAID, as recommended by evidence-based guidelines) than all other patients. Findings also suggest that some patients may benefit from DTCA. The authors discuss the need for balanced drug information for consumers, increased physician vigilance in prescribing appropriately, and further study of DTCA.

Key Words: advertising • drug utilization • prescriptions • drugs • physician-patient relations

Medical Care Research and Review, Vol. 62, No. 5, 544-559 (2005)
DOI: 10.1177/1077558705279314


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Lurie DTC Advertising Harms Patients and Should Be Tightly Regulated. J. Law Med. Ethics, September 1, 2009; 37(3): 444 - 450. [PDF]

				B. Mintzes Should Canada allow direct-to-consumer advertising of prescription drugs?: NO Can Fam Physician, February 1, 2009; 55(2): 131 - 133. [Full Text] [PDF]

				B. Mintzes Le Canada devrait-il autoriser la publicite directe des medicaments d'ordonnance?: NON Can Fam Physician, February 1, 2009; 55(2): 135 - 138. [Full Text] [PDF]

				B. Parnes, P. C. Smith, C. Gilroy, J. Quintela, C. B. Emsermann, L. M. Dickinson, and J. M. Westfall Lack of Impact of Direct-to-Consumer Advertising on the Physician-Patient Encounter in Primary Care: A SNOCAP Report Ann. Fam. Med, January 1, 2009; 7(1): 41 - 46. [Abstract] [Full Text] [PDF]

				P. Rutter and S. Gilbody The European pharmaceutical industry: coming to a screen near you? J R Soc Med, October 1, 2008; 101(10): 485 - 488. [Full Text] [PDF]

				H. V Danesh-Meyer and L. A Levin Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol, November 1, 2007; 91(11): 1551 - 1555. [Abstract] [Full Text] [PDF]

				D Klein, A MacDonald, N Drummond, and A Cave A qualitative study to identify factors influencing COXIB prescribed by family physicians for musculoskeletal disorders Fam. Pract., December 1, 2006; 23(6): 659 - 665. [Abstract] [Full Text] [PDF]

				B. L. Strom How the US drug safety system should be changed. JAMA, May 3, 2006; 295(17): 2072 - 2075. [Full Text] [PDF]